Autosomal Dominant Charcot-Marie-Tooth Disease with Focally Folded Myelin Sheaths Type 1a

Autosomal dominant Charcot–Marie–Tooth disease with focally folded myelin sheaths type 1A is a very rare form of Charcot–Marie–Tooth disease (CMT) type 1A. It is an inherited nerve disease that mainly damages the long nerves to the feet and hands. “Autosomal dominant” means a child can get the condition if they inherit one changed gene from either mother or father. Genetic Diseases Info Center+2National Organization for Rare Disorders+2

Autosomal dominant Charcot-Marie-Tooth disease with focally folded myelin sheaths type 1A is usually called CMT1A. It is a genetic nerve disease where an extra copy of the PMP22 gene makes too much PMP22 protein. This damages the myelin sheath, the “insulation” around peripheral nerves, and in some people the myelin looks focally folded under the microscope. This slow damage causes weakness and wasting in the feet, legs, and later the hands, plus loss of feeling and problems with balance. The condition is autosomal dominant, which means one changed copy of the gene is enough to cause the disease, and it often runs in families. There is no cure yet, but many treatments can support walking, hand function, pain control, and quality of life. CAGS+3Disease Ontology+3PMC+3

In this subtype, the basic problem is usually an extra copy (duplication) or a disease-causing change (mutation) in a gene called PMP22 on chromosome 17. PMP22 makes a protein that is needed for healthy myelin. Myelin is the “insulation” around nerves that helps electrical signals move quickly. When there is too much or faulty PMP22, the myelin becomes unstable and breaks down, which slows or blocks nerve signals. Nature+3Nature+3ScienceDirect+3

The phrase “with focally folded myelin sheaths” describes what doctors see under a microscope in a nerve biopsy. Myelin sometimes folds and bunches up in small areas (focal folds). These folds show severe stress and damage in the myelin, and similar changes are described in some forms of CMT, especially types linked to myelin proteins. PubMed+2Springer Nature+2

Over time, this disease slowly causes weakness and wasting of the muscles of the feet, lower legs, and later the hands, along with numbness, tingling, and loss of reflexes. Foot deformities such as high arches and hammer toes are very common. The condition usually starts in childhood or teenage years and then progresses slowly through life. Wikipedia+4Genetic Diseases Info Center+4National Organization for Rare Disorders+4

Other names

Below are other names and codes that refer to the same disease or very closely related forms:

• Charcot–Marie–Tooth disease type 1A (CMT1A) – This is the usual name for the PMP22-related demyelinating form of CMT; our subtype is a special variant where myelin can look focally folded on biopsy. Genetic Diseases Info Center+2National Organization for Rare Disorders+2

• Charcot–Marie–Tooth neuropathy type 1A – “Neuropathy” means a disease of nerves; type 1A tells us it is the demyelinating, PMP22-based form. National Organization for Rare Disorders+1

• Autosomal dominant Charcot–Marie–Tooth disease with focally folded myelin sheaths type 1A – A more detailed synonym that adds the inheritance pattern (autosomal dominant) and the special biopsy feature (focally folded myelin). ZFIN+2Monarch Initiative+2

• Hereditary motor and sensory neuropathy type 1A (HMSN1A) – “Hereditary” means inherited, “motor and sensory” shows that both movement and feeling nerves are affected, and type 1A is again the classic PMP22-related subtype. ZFIN+2ClinGen+2

• Microduplication 17p12 / 17p11.2-p12 duplication neuropathy – These names describe the chromosomal abnormality: a small extra piece (microduplication) of the short arm of chromosome 17 where PMP22 sits. ClinGen+3JKMS+3Nature+3

Types

Doctors may talk about “types” or “forms” of CMT1A with focally folded myelin sheaths based on age of onset, severity, and test findings, even though all share the same basic PMP22 problem. PMC+3ResearchGate+3Taylor & Francis Online+3

• Early-onset severe form – Symptoms such as delayed walking, frequent falls, and early foot deformities appear in childhood. These children often have very slow nerve conduction on tests and more marked weakness and scoliosis (spine curve). Wikipedia+3PMC+3ScienceDirect+3

• Classic adolescent-onset form – Many patients develop symptoms around school age or teenage years, with ankle weakness, tripping, and gradual development of high-arched feet. Nerve tests show demyelinating changes, and genetic tests reveal PMP22 duplication. New England Journal of Medicine+3Genetic Diseases Info Center+3National Organization for Rare Disorders+3

• Adult-onset mild form – Some people notice symptoms only in adulthood, such as mild foot drop or hand clumsiness. They may be diagnosed later, sometimes after a child in the family is tested, showing that the disease can have very different severity even inside one family. Wikipedia+3ResearchGate+3Taylor & Francis Online+3

• Form with focally folded myelin sheaths on biopsy – In a small number of patients, nerve biopsy shows myelin that is focally folded or “out-pouched” rather than smoothly wrapped. This pattern has been described in several demyelinating CMT subtypes, including some PMP22- and MPZ-related cases. It may be linked to particular mutations that disturb myelin structure. ZFIN+3PubMed+3Springer Nature+3

• Form with strong influence of other diseases (comorbidities) – People who also have diabetes, thyroid disease, or other conditions that damage nerves can have more severe symptoms than those with CMT1A alone, even though the underlying genetic cause is the same. American Academy of Neurology+3PubMed+3ScienceDirect+3

Causes

Remember: the primary cause is genetic. All other “causes” below are ways that this gene problem starts or becomes worse.

1. PMP22 gene duplication – Most CMT1A cases are caused by a 1.4–1.5 Mb duplication on chromosome 17 that includes PMP22. This extra copy makes too much PMP22 protein, which damages myelin and leads to the disease. ClinGen+3JKMS+3Nature+3

2. Disease-causing PMP22 point mutations – Some people have single-letter changes in PMP22 instead of a full duplication. These mutations can change the shape or behavior of PMP22 so that myelin forms poorly or breaks down more easily. Journal of Neuroscience+3PMC+3American Chemical Society Publications+3

3. Autosomal dominant inheritance – If a parent has a PMP22 duplication or mutation, each child has about a 50% chance of inheriting it. This vertical transmission through generations is a key causal factor. Wikipedia+3Genetic Diseases Info Center+3National Organization for Rare Disorders+3

4. De novo (new) PMP22 duplication – Sometimes the duplication arises for the first time in a child during egg or sperm formation, even when both parents are unaffected. This new event is a direct genetic cause in that person. ResearchGate+2Taylor & Francis Online+2

5. Gene dosage effect of PMP22 – PMP22 is dosage-sensitive. Having three copies (trisomy for this gene) instead of the usual two strongly disturbs Schwann cell function and myelin stability, creating chronic demyelinating neuropathy. PMC+3Nature+3Nature+3

6. Abnormal Schwann cell myelin formation – Schwann cells produce myelin in peripheral nerves. When PMP22 levels are abnormal, Schwann cells build myelin that is unstable, leading to segmental demyelination and sometimes focally folded myelin in nerve biopsies. Springer Nature+4PMC+4ResearchGate+4

7. Secondary axonal degeneration – Long-standing demyelination exposes and injures axons. Over time, the nerve fibers themselves degenerate, which adds to weakness and numbness. This axon loss is a major part of disability in CMT1A. Wikipedia+2PMC+2

8. Focally folded myelin as a structural defect – In this subtype, local areas of myelin fold back or form “loops,” creating abnormal thick segments. These folds are thought to reflect severe local stress on the myelin membrane and errors in how myelin wraps around the axon. PubMed+2Springer Nature+2

9. Rare complex copy-number changes in 17p12 – Some families have unusual rearrangements or extra-large duplications around PMP22. These complex changes alter gene dosage or surrounding regulatory regions and can modify the disease. Nature+3ResearchGate+3Taylor & Francis Online+3

10. Other genetic modifiers (other CMT genes) – Mutations or variants in other myelin genes (such as MPZ, EGR2, or NEFL) can coexist and may change severity, sometimes leading to atypical features or more pronounced myelin folding. PMC+3Wikipedia+3Muscular Dystrophy Association+3

11. Family-specific background genes – Even when the same PMP22 duplication is present, members of the same family often show different levels of weakness or deformity. This suggests that many small background genetic differences influence how strongly the disease appears. ResearchGate+2Taylor & Francis Online+2

12. Coexisting diabetes mellitus – Diabetes itself can cause neuropathy. When it appears in someone with CMT1A, research shows that nerve damage and clinical scores are worse than in CMT1A alone, so diabetes acts as a strong worsening factor. PMC+3PubMed+3ScienceDirect+3

13. Other metabolic diseases (e.g., thyroid problems) – Conditions such as hypothyroidism or vitamin B12 deficiency can also harm nerves. In a person with CMT1A, these extra problems can accelerate symptoms, even though they do not create the genetic disease by themselves. Wikipedia+2Wikipedia+2

14. Repetitive nerve compression and trauma – Because the myelin is already fragile, minor compression (tight shoes, frequent crossing of legs, leaning on elbows) can more easily injure nerves and worsen weakness or numbness. Similar sensitivity to pressure is well known in related PMP22 disorders. Wikipedia+2JKMS+2

15. Poorly fitting footwear and biomechanical stress – High-arched, unstable feet concentrate pressure on small areas. Without supportive shoes and insoles, this mechanical stress can speed up foot deformity and pain in CMT. RSNA Publications+3PMC+3ScienceDirect+3

16. Obesity and physical inactivity – Extra body weight and low muscle use put more load on weak ankles and feet. This can worsen balance, increase falls, and may make nerve symptoms more disabling, even though it is not a primary genetic cause. Frontiers+3Wikipedia+3Murdoch Children’s Research Institute+3

17. Infections that stress peripheral nerves – Severe or repeated infections, especially those that cause high fever or systemic inflammation, can temporarily worsen nerve function and may unmask previously mild CMT symptoms. Wikipedia+2Wikipedia+2

18. Use of known neurotoxic drugs – Some chemotherapy medications and other toxic agents can damage peripheral nerves. In someone with CMT1A, these drugs can cause more intense neuropathy than in people without a pre-existing genetic neuropathy. Wikipedia+2Wikipedia+2

19. Lack of physiotherapy and joint protection – Without early stretching, strengthening, and protective bracing, joint contractures and deformities progress faster, so disability becomes worse even though the genetic cause is the same. Murdoch Children’s Research Institute+2Wikipedia+2

20. Psychological and social stress leading to under-use – Fear of falling, pain, and social stigma can make patients move less. Long periods of under-use cause muscle wasting and reduced balance, which can make the inherited nerve problem more obvious and disabling. Wikipedia+2Murdoch Children’s Research Institute+2

Symptoms

1. Distal muscle weakness in feet and ankles – The earliest sign is often weakness of the small muscles that lift the foot and toes. People trip, struggle to run, or cannot walk on heels. This pattern is typical of demyelinating CMT, where the longest nerves are affected first. Muscular Dystrophy Association+3Wikipedia+3Murdoch Children’s Research Institute+3

2. Foot drop and high-stepping gait – Because the front of the foot does not lift well, the person may lift the knees higher than normal to avoid dragging the toes. This “steppage” gait is very typical in CMT and related neuropathies. Wikipedia+2Murdoch Children’s Research Institute+2

3. High-arched feet (pes cavus) – Over time, muscle imbalance pulls the foot into a high arch with clawed toes. This deformity is strongly associated with hereditary neuropathies such as CMT and is a common clue for diagnosis. Murdoch Children’s Research Institute+3PMC+3ScienceDirect+3

4. Hammer or claw toes – Weakness of some toe muscles and over-pull of others leads to bent or clawed toes. These can rub inside shoes, cause corns, and make balance more difficult. PMC+2Murdoch Children’s Research Institute+2

5. Calf muscle wasting (“inverted champagne bottle” legs) – The muscles around the lower leg shrink, making the calves look thin above relatively normal knees or thighs. This classic appearance reflects chronic denervation. Wikipedia+2Murdoch Children’s Research Institute+2

6. Distal hand weakness and clumsiness – Later in the disease, the small muscles of the hands are involved, causing difficulty with buttons, writing, or fine tasks. This happens as the disease gradually moves up the arms. Wikipedia+2Wikipedia+2

7. Numbness and reduced sensation in feet and hands – Patients report numbness, tingling, or “walking on cotton.” Sensory loss often starts in the toes and spreads upward in a “stocking-glove” pattern. Wikipedia+3Wikipedia+3Wikipedia+3

8. Loss of tendon reflexes (especially ankle jerks) – Reflex testing often shows absent or very reduced ankle reflexes, and sometimes knee reflexes, due to poor conduction of signals in damaged peripheral nerves. PMC+3Murdoch Children’s Research Institute+3Wikipedia+3

9. Neuropathic pain or discomfort – Some patients have burning, aching, or shooting pain in feet and legs. This pain comes from irritated or damaged sensory fibers. Others have little or no pain but still have weakness and numbness. Wikipedia+2Wikipedia+2

10. Balance problems and frequent falls – Weak ankles, numb soles, and foot deformities make balance hard, especially on uneven ground or in the dark. Falls and ankle sprains are therefore common. RSNA Publications+3Murdoch Children’s Research Institute+3PMC+3

11. Fatigue with walking or standing – Because muscles are weak and nerves work poorly, walking or standing for long periods is tiring. Many patients need frequent rests or use supports such as ankle–foot orthoses. Murdoch Children’s Research Institute+2Wikipedia+2

12. Scoliosis or other skeletal deformities – Some people develop curvature of the spine or knee and hip alignment problems, due to chronic muscle imbalance and altered gait. Wikipedia+3PMC+3ScienceDirect+3

13. Tremor or shakiness in some forms – A fine tremor of the hands or body posture (as seen in related syndromes such as Roussy–Lévy) can appear, reflecting involvement of sensory and motor control pathways. Wikipedia+2Wikipedia+2

14. Slow progression over many years – Symptoms usually worsen slowly. Many patients remain able to walk for decades, but may need braces or mobility aids as they age. The slow course is typical of CMT1A. PMC+3Genetic Diseases Info Center+3National Organization for Rare Disorders+3

15. Worsening with comorbid conditions (e.g., diabetes) – When diabetes or other neuropathy-causing illnesses are present, strength and sensation can decline more quickly, and disability scores are higher. American Academy of Neurology+3PubMed+3ScienceDirect+3

Diagnostic tests

Diagnosis combines clinical examination, electrical studies, genetic testing, and sometimes nerve imaging or biopsy. This is especially important when focally folded myelin is suspected. Wikipedia+3Genetic Diseases Info Center+3National Organization for Rare Disorders+3

Physical exam tests

1. Full neurological examination – The doctor checks strength, tone, reflexes, and sensation in all limbs. Typical findings include distal weakness, reduced reflexes, and length-dependent sensory loss, which strongly suggest a length-dependent peripheral neuropathy such as CMT1A. Muscular Dystrophy Association+3Wikipedia+3Murdoch Children’s Research Institute+3

2. Gait and walking assessment – The clinician watches how the patient walks, looking for foot drop, high-stepping gait, ankle instability, or need for orthoses. This visual assessment can reveal how far the disease has progressed and helps distinguish CMT from muscle or brain disorders. RSNA Publications+3Murdoch Children’s Research Institute+3PMC+3

3. Foot and spine inspection – The doctor examines feet for pes cavus, hammer toes, calluses, and checks the back for scoliosis. Marked cavus and claw toes in a young person are strong clues to hereditary neuropathy. ResearchGate+3PMC+3ScienceDirect+3

4. Sensory examination of vibration and joint position – Using a tuning fork and gentle movement of toes and fingers, the doctor evaluates vibration and position sense. Loss of these sensations supports a length-dependent peripheral sensory neuropathy. PMC+3Wikipedia+3Wikipedia+3

Manual tests and functional scales

5. Manual muscle testing (MRC grading) – Muscles are graded from 0 (no movement) to 5 (normal strength). In CMT1A, ankle dorsiflexion and toe extensors are often weakest. Tracking these scores over time helps measure progression. Wikipedia+2PMC+2

6. 10-meter walk test – The time needed to walk 10 meters at a comfortable speed is recorded. Slower speed or clear foot drop compared to normal values shows functional impact of the neuropathy. Murdoch Children’s Research Institute+2Wikipedia+2

7. 6-minute walk test – The distance walked in 6 minutes is measured to assess endurance. In CMT1A, distances are often reduced and correlate with disease severity scores and MRI signs of muscle involvement. Frontiers+2Nature+2

8. Grip strength testing – A hand dynamometer measures how strongly the patient can squeeze. Reduced grip strength reflects distal hand weakness and is useful for following progression and response to therapy. Wikipedia+2PMC+2

Lab and pathological tests

9. Routine blood tests to exclude other neuropathies – Blood sugar, B12, thyroid hormone, kidney and liver tests are done to rule out other frequent causes of neuropathy that could mimic or worsen CMT. This helps confirm that a genetic cause is most likely. PubMed+3Wikipedia+3Wikipedia+3

10. Autoimmune and inflammatory neuropathy panels (when needed) – If the pattern is unusual, tests such as ESR, CRP, autoantibodies, or serum protein electrophoresis may be done to exclude acquired inflammatory neuropathies. A negative work-up supports a hereditary cause. Wikipedia+2Wikipedia+2

11. Molecular genetic test for PMP22 duplication – Techniques such as MLPA or other copy-number assays are used to look for the classic 17p12 duplication. Finding this duplication confirms CMT1A and fits with the “autosomal dominant CMT with focally folded myelin sheaths type 1A” label. ZFIN+3JKMS+3Nature+3

12. Family genetic testing (segregation analysis) – Testing parents and siblings helps show whether the variant tracks with disease in the family. This supports the diagnosis and clarifies inheritance for genetic counseling. Wikipedia+3Genetic Diseases Info Center+3National Organization for Rare Disorders+3

13. Expanded CMT gene panel sequencing – If PMP22 tests are negative or if features are atypical, multi-gene sequencing panels can check many CMT genes at once, including MPZ, GJB1, MFN2, NEFL and others. This helps separate CMT1A with folded myelin from CMT1B or other subtypes with similar pathology. PMC+3Wikipedia+3Muscular Dystrophy Association+3

14. Nerve biopsy with light microscopy and special stains – In unclear cases, a small sensory nerve (often sural nerve) is removed for study. Under the microscope, doctors can see demyelination, remyelination, onion bulbs, and in this subtype, focally folded myelin sheaths. This pattern supports a diagnosis of hereditary demyelinating neuropathy. Wikipedia+3PubMed+3Springer Nature+3

Electrodiagnostic tests

15. Nerve conduction studies (NCS) – Electrodes are placed on the skin to measure how fast and how strong signals travel along nerves. In CMT1A, conduction velocities are uniformly slowed, and amplitudes may be reduced, showing a diffuse demyelinating neuropathy. PMC+3Wikipedia+3Genetic Diseases Info Center+3

16. Electromyography (EMG) – A fine needle records electrical activity from muscles. EMG in CMT1A often shows chronic denervation and reinnervation patterns, confirming that weakness comes from nerve rather than muscle disease. Wikipedia+2PMC+2

17. F-wave and late response studies – These special NCS measurements look at how signals travel along the whole length of motor nerves. Prolonged or absent F-waves support a generalized demyelinating neuropathy. Wikipedia+2PMC+2

18. Somatosensory evoked potentials (SSEPs) – Small electrical stimuli are given to the limbs and recordings are made from the spinal cord or brain. Delayed responses show slow sensory conduction and support widespread demyelination. Wikipedia+2PMC+2

Imaging tests

19. Peripheral nerve ultrasound – High-resolution ultrasound can show enlarged peripheral nerves in CMT1A and related CMT subtypes. Studies have shown that nerve cross-sectional area is increased and that ultrasound may help distinguish CMT1A from other demyelinating neuropathies. UMBC Journal+3PubMed+3American Academy of Neurology+3

20. Magnetic resonance neurography and limb MRI – MRI of nerves and leg muscles can show nerve enlargement, abnormal signal, and fatty replacement of muscles. In CMT1A, MR neurography and diffusion tensor imaging detect peripheral nerve abnormalities and correlate with clinical severity, making MRI a valuable research and sometimes clinical tool. RSNA Publications+3PubMed+3Wiley Online Library+3

Non-pharmacological treatments

1. Individualized physical therapy exercise program
   A regular program with a physiotherapist is one of the most important treatments for CMT1A. The main goals are to keep muscles as strong as possible, preserve joint movement, and delay contractures and deformities. Exercises are usually low-impact and tailored to each person’s weakness pattern. Simple strengthening, gentle resistance work, and functional training (sit-to-stand, step-ups, walking practice) can improve walking, reduce fatigue, and protect joints from long-term damage. PMC+2PubMed+2

2. Stretching and range-of-motion exercises
   Because weak muscles cannot hold joints in a normal position, tightness and deformity can develop in the calves, feet, and hands. Daily stretching of calves, hamstrings, and foot muscles, plus gentle ankle and toe movements, helps keep joints flexible. Therapists may teach simple stretches that can be done at home or before walking. This can reduce cramps, delay fixed foot deformities like high arches or hammer toes, and make fitting shoes and braces easier. CMT Australia+1

3. Balance and gait (walking) training
   Nerve damage in CMT1A affects balance and coordination, so many people trip or fall. Balance training uses simple tasks like standing on different surfaces, stepping in different directions, or walking in safe obstacle courses. Therapists may also use treadmills with harness support. These exercises help the brain learn new balance strategies and can make everyday walking safer and more efficient. MDPI+1

4. Endurance and aerobic exercise
   Gentle aerobic exercise such as swimming, cycling, or walking helps heart and lung health, prevents weight gain, and can improve fatigue. In CMT1A, the aim is moderate activity without pushing muscles to exhaustion, because over-fatigue can worsen weakness. Programmes usually start slowly and increase over weeks. This kind of training can improve stamina for daily life without harming nerves. Journal of Health and Allied Sciences NU+2OAM Journal of Medical Sciences+2

5. Occupational therapy for hand and daily activities
   Occupational therapists focus on hand function and self-care tasks like dressing, writing, and using tools or keyboards. They may teach energy-saving techniques, suggest adapted pens or cutlery, and design simple strategies to make cooking, bathing, and school or office work safer and easier. This support reduces frustration and keeps independence for as long as possible. nhs.uk+1

6. Ankle-foot orthoses (AFOs) and foot orthotics
   Braces and shoe inserts are central in CMT1A care. AFOs and custom insoles help lift the front of the foot, support weak ankles, and correct abnormal foot positions. They reduce tripping, improve gait symmetry, and can decrease joint pain. An orthotist assesses the person’s walking pattern and designs devices that can be adjusted as the disease slowly progresses. PMC+3nhs.uk+3Charcot-Marie-Tooth Association+3

7. Custom footwear and shoe modifications
   Many people with CMT1A have high arches and clawed toes, which make standard shoes uncomfortable. Extra-depth shoes, rocker-bottom soles, or shoes with special insoles can ease pressure points and work together with AFOs. Proper footwear improves stability and may prevent skin sores and calluses that occur when deformities rub inside tight shoes. www.slideshare.net+1

8. Hand and wrist splints
   When hand muscles weaken, the fingers and thumb may drift into awkward positions, making it hard to grip. Soft or rigid splints can support the thumb or wrist in a more functional posture, improving pinch and grasp. Splints are often used for specific tasks, such as writing or using a keyboard, and can reduce joint strain and pain. nhs.uk+1

9. Walking aids (sticks, crutches, walkers)
   Simple walking aids can make a big difference in safety. A cane or trekking pole may help with mild balance problems, while forearm crutches or walkers can help people who have weaker legs or severe deformities. Therapists teach correct use so that the device supports balance without causing shoulder or wrist pain. Muscular Dystrophy Association+1

10. Posture and spine care
    Weak leg and trunk muscles sometimes lead to abnormal posture in standing and sitting. Over time, this can cause back or neck pain. Physiotherapists may teach core-strengthening exercises, ergonomic sitting positions, and gentle back stretches. Good posture reduces strain on joints and may slow spine problems such as scoliosis that can appear in some people with CMT. Muscular Dystrophy Association+1

11. Pain self-management education
    People with CMT can have both nerve pain (burning, shooting) and musculoskeletal pain (from joints and muscles). Education explains the difference and teaches pacing of activity, use of braces or cushions, heat or cold packs, relaxation techniques, and when to use medicines. Understanding pain types helps people choose the safest and most effective strategies, often reducing the need for higher drug doses. Charcot-Marie-Tooth Association+2CMT Australia+2

12. Fall-prevention and home modifications
    Removing loose rugs, improving lighting, adding grab bars, and using non-slip mats in bathrooms are low-cost ways to reduce falls. An occupational therapist can visit the home and suggest small changes, such as raised toilet seats or handrails, that give extra security. This is especially important for people with frequent trips, severe foot drop, or balance problems. nhs.uk+1

13. Hydrotherapy or aquatic therapy
    Exercise in warm water lets people move weak muscles without bearing full body weight. The water supports the body and allows smoother walking practice, gentle resistance exercises, and stretching. Many patients feel less pain in water and can work longer than on land, which may help strength, flexibility, and confidence. MDPI+1

14. Technology-assisted rehabilitation (treadmill, virtual reality, robotics)
    Some centres use body-weight–supported treadmills, computer-based balance games, or robotic devices to help with walking and balance training. In CMT, early studies suggest these tools may improve endurance and dynamic balance, but they are not yet widely available and are usually added to, not replacing, standard physiotherapy. MDPI+1

15. Psychological support and counselling
    Living with a chronic inherited disease can lead to worry, low mood, or social withdrawal. Talking therapy, support groups, or online communities can help people share experiences and develop coping skills. Good mental health can improve motivation to follow exercise plans and attend regular check-ups. Muscular Dystrophy Association+1

16. Genetic counselling and family planning support
    Because CMT1A is autosomal dominant, each child of an affected person has a 50% chance of inheriting the mutation. Genetic counselling explains inheritance patterns, available tests, and options for family planning. It also helps relatives understand their own risk and when to seek evaluation. Disease Ontology+1

17. Education about nerve-toxic drugs and lifestyle risks
    Some medicines and toxins can worsen neuropathy. CMT charities and guidelines provide lists of drugs that should be avoided or used with caution. Smoking and heavy alcohol use may also harm nerves. Learning to avoid these triggers is a simple way to protect remaining nerve function. nhs.uk+2Muscular Dystrophy Association+2

18. Weight management and healthy lifestyle coaching
    Extra body weight puts more strain on weak ankles and feet, increases fatigue, and may raise the risk of diabetes, which can add further neuropathy. Nutrition advice and realistic activity goals help people reach and maintain a healthy weight, supporting easier walking and overall health. Muscular Dystrophy Association+1

19. Vocational rehabilitation and school/work adaptations
    Specialists can help adjust work tasks, tools, and schedules to match physical abilities. This might include flexible hours, remote work, assistive technology, or job retraining. For students, it may mean extra time for exams, accessible classrooms, or adapted sports. These changes help people stay engaged in school or employment. Muscular Dystrophy Association+1

20. Regular multi-disciplinary follow-up
    The best care usually comes from a team that includes a neurologist, physiatrist, physiotherapist, occupational therapist, orthotist, and sometimes a surgeon and pain specialist. Regular reviews allow early detection of deformities or complications and timely adjustment of braces, exercises, or medications. Muscular Dystrophy Association+2ScienceDirect+2

---

Drug treatments

Important safety note: No medicine currently cures CMT1A. Drug treatment is mainly for nerve pain, muscle and joint pain, mood, and associated problems. Doses must always be set by a doctor; the brief “dosage” notes below are general and based on FDA-approved labels or neuropathic pain guidelines, not personal medical advice. Muscular Dystrophy Association+1

1. Gabapentin (Neurontin and similar)
   Gabapentin is an anti-seizure drug widely used to treat neuropathic pain. It reduces abnormal pain signals in damaged nerves and is often used when people feel burning, shooting, or electric-shock pains in feet and legs. Typical treatment starts with a low dose divided during the day and is slowly increased to the lowest effective dose within the approved range. Common side effects include sleepiness, dizziness, and swelling of legs, so doctors increase doses carefully and avoid sudden stops. FDA Access Data+2Springer Nature+2

2. Pregabalin (Lyrica)
   Pregabalin is related to gabapentin and is also approved for several neuropathic pain conditions. It binds to calcium channels in nerve cells and reduces the release of excitatory neurotransmitters, calming overactive pain pathways. It is usually taken one to three times a day, starting at a low dose and titrated upward. Side effects can include dizziness, drowsiness, weight gain, and leg swelling, so regular review is important. Springer Nature+3FDA Access Data+3FDA Access Data+3

3. Duloxetine (Cymbalta)
   Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for diabetic peripheral neuropathic pain and other conditions. By increasing serotonin and norepinephrine in pain pathways, it helps reduce chronic neuropathic pain and can also improve mood. It is usually taken once daily at a dose in the FDA-approved range, with gradual dose changes. Nausea, dry mouth, sleep changes, and increased sweating are possible side effects, and it should not be combined with certain antidepressants or MAO inhibitors. FDA Access Data+2PMC+2

4. Venlafaxine (SNRI antidepressant)
   Venlafaxine is another SNRI sometimes used off-label for neuropathic pain when duloxetine or other options are not suitable. It works similarly by boosting serotonin and norepinephrine, which can dampen pain transmission in the spinal cord. It is usually given once or twice daily in extended-release form. Side effects may include increased blood pressure, insomnia or sedation, and stomach upset, so monitoring is required. Charcot-Marie-Tooth Association+1

5. Amitriptyline (tricyclic antidepressant)
   Amitriptyline is an older antidepressant often used at low doses at night for nerve pain. It blocks reuptake of serotonin and norepinephrine and has additional actions on various receptors, which together reduce pain but also cause side effects such as dry mouth, constipation, weight gain, and drowsiness. It is usually started at a small bedtime dose and increased carefully, especially in older adults or people with heart disease. FDA Access Data+2FDA Access Data+2

6. Nortriptyline (tricyclic antidepressant)
   Nortriptyline has similar effects to amitriptyline but is sometimes better tolerated. It is used off-label for neuropathic pain in low bedtime doses and adjusted according to response and side effects. Common adverse effects include dry mouth, dizziness, and constipation, and it is not suitable for everyone, especially people with certain heart rhythm problems. Springer Nature+1

7. Topical lidocaine 5% patches or gels
   Lidocaine patches or gels can be used on limited painful skin areas, for example a small part of the foot. Lidocaine blocks sodium channels in local nerve endings and reduces pain signals without much effect on the whole body. Patches are usually applied for a set number of hours then removed. Skin irritation and numbness in the area are the main side effects, and patches should not be used on broken skin. Springer Nature+1

8. Capsaicin high-concentration patch (Qutenza, 8%) – specialist use
   Qutenza is a high-dose capsaicin patch approved for neuropathic pain such as post-herpetic neuralgia. It is applied in a clinic by trained staff after local anaesthetic. Capsaicin strongly stimulates TRPV1 pain receptors, then leads to a temporary reduction of their function and of small nerve endings, giving long-lasting pain relief for some patients. Application can be painful, and blood pressure may rise during treatment, so careful monitoring is required. It is not self-applied at home. FDA Access Data+2FDA Access Data+2

9. Non-steroidal anti-inflammatory drugs (NSAIDs)
   Medicines like ibuprofen or naproxen do not treat nerve damage but can help with joint and muscle pain caused by abnormal walking, deformities, or overuse. They work by blocking prostaglandin production, which reduces inflammation and pain. They should be used at the lowest effective dose and shortest duration, and avoided or used with caution in people with stomach ulcers, kidney disease, or certain heart problems. Muscular Dystrophy Association+1

10. Acetaminophen (paracetamol)
    Paracetamol is often used for mild to moderate musculoskeletal pain and can be combined with other treatments. It acts mainly in the central nervous system to reduce pain and fever. It is generally safe at recommended total daily doses, but overdose can seriously damage the liver, so people must avoid exceeding the maximum daily amount or combining multiple paracetamol-containing products. Muscular Dystrophy Association+1

11. Short-term muscle relaxants (for cramps and spasm)
    Some patients have painful muscle cramps or stiffness. Short-term use of muscle relaxants such as baclofen or tizanidine may help, especially at night, by reducing excessive muscle firing. These drugs can cause drowsiness, dizziness, and sometimes low blood pressure, so they must be used carefully and not abruptly stopped after long-term use. Muscular Dystrophy Association+1

12. Tramadol (weak opioid with SNRI effect)
    Tramadol is sometimes used as a second-line medicine when other neuropathic pain drugs are not enough. It acts partly on opioid receptors and partly on serotonin and norepinephrine, giving pain relief but also a risk of nausea, dizziness, constipation, and dependence. Guidelines usually recommend limiting opioid use and reviewing regularly to avoid long-term problems. Springer Nature+1

13. Other opioids (only in selected severe cases)
    Stronger opioids like oxycodone or morphine may be considered only for severe pain that has not responded to other therapies and under close specialist supervision. They work by binding to opioid receptors and strongly reducing pain signals but carry high risks of tolerance, dependence, constipation, sleepiness, and breathing problems. In many CMT patients, non-opioid options are preferred whenever possible. Springer Nature+1

14. Sleep medicines in selected patients
    Severe pain or discomfort may disturb sleep. In some cases, short-term use of sleep aids or sedating antidepressants at low dose may be used to help restorative sleep while neuropathic pain is being treated. These medicines can cause daytime drowsiness and must not be combined with alcohol or other sedatives without medical guidance. Non-drug sleep hygiene is always the first step. Springer Nature+1

15. Antidepressants for mood and pain coping
    Living with chronic pain and disability can cause depression or anxiety, which in turn worsen pain perception. SSRIs or SNRIs may be prescribed to treat mood disorders as well as indirectly help pain by improving coping. Choice of drug depends on the person’s age, other illnesses, and possible interactions with neuropathic pain medicines. Springer Nature+1

16. Anti-tremor or anti-spasticity drugs when needed
    Some people with CMT develop tremors or spasticity. Medicines such as propranolol for tremor or baclofen for spasticity may be used in selected cases. They have specific risks (for example, low blood pressure or sedation) and must be prescribed and monitored by a specialist. Muscular Dystrophy Association+1

17. Vitamin D supplementation (when deficient)
    Vitamin D deficiency is common worldwide and can worsen bone health and muscle weakness. Measuring vitamin D levels and replacing low levels with standard doses can support bone strength and reduce fracture risk in people with foot deformities or balance problems. Supplementation should follow national guidelines and blood levels should be checked. Muscular Dystrophy Association+1

18. Treatment of co-existing diabetes or thyroid disease
    If a person with CMT also has diabetes or thyroid problems, proper treatment of these conditions may reduce extra nerve damage. Standard diabetes and thyroid medicines are used following general guidelines. Good control can slow added neuropathy and improve symptoms like fatigue and pain. ScienceDirect+1

19. Experimental drug PXT3003 (under investigation)
    PXT3003 is an oral combination (baclofen, naltrexone, sorbitol) being studied specifically for CMT1A. It aims to reduce PMP22 overexpression and improve nerve function. Phase 2 and 3 trials have shown promising effects on disability scores, but this medicine is not yet widely approved and is available only in clinical trials or limited settings. Springer Nature+3ClinicalTrials+3PMC+3

20. Other trial medicines and future targeted therapies
    Several experimental drugs and genetic approaches are under study, such as small molecules that lower PMP22 expression, aldose reductase inhibitors, and therapies guided by gene editing. These are not standard treatment and can only be accessed in clinical trials. Participation must be discussed with a CMT expert and trial centre. ScienceDirect+2Springer Nature+2

---

Dietary molecular supplements

Evidence for supplements in CMT1A is limited. They should never replace prescribed treatments, and doses must be discussed with a doctor to avoid interactions or toxicity.

1. Omega-3 fatty acids (fish oil)
   Omega-3 fatty acids have anti-inflammatory and membrane-stabilising effects and may support nerve cell health. They might help general cardiovascular health and could modestly improve neuropathic pain or inflammation. Typical intakes use standard fish-oil or algae-oil products within commonly recommended daily ranges. Side effects can include stomach upset and, at high doses, increased bleeding tendency, especially with blood-thinning drugs. ScienceDirect+1

2. Alpha-lipoic acid
   Alpha-lipoic acid is an antioxidant widely studied in diabetic neuropathy. It helps scavenge free radicals and may improve blood flow and nerve conduction in some neuropathy patients, though evidence in CMT is lacking. It is usually taken orally at doses used in clinical trials, under medical supervision. Side effects may include nausea and low blood sugar in people taking diabetes medicines. Springer Nature+1

3. Coenzyme Q10
   Coenzyme Q10 supports mitochondrial energy production and has been explored in various neuromuscular disorders. Theoretically, better energy handling could help weak muscles cope with daily activity. Supplements are taken in divided daily doses with fat-containing food. They are generally well tolerated but can cause stomach upset or interact with blood thinners, so medical advice is important. ScienceDirect+1

4. B-complex vitamins (especially B1, B6, B12)
   B vitamins are essential for normal nerve function. Deficiency (for example in B12) can itself cause neuropathy. In CMT, correcting any deficiency is important, though high-dose B6 can actually damage nerves. Standard multivitamin doses are usually safe, but high-dose therapy must be supervised and based on blood levels. Springer Nature+1

5. Vitamin D (if low)
   As mentioned above, vitamin D helps bone and muscle health. Supplementation at guideline doses for deficient people can reduce fracture risk and support muscle function, especially in those with reduced mobility. Regular blood tests help keep levels in the safe range and avoid toxicity. Muscular Dystrophy Association+1

6. Magnesium
   Magnesium is important for muscle relaxation and nerve conduction. Some people take it to help with cramps or restless legs, but strong data in CMT are lacking. Usual supplemental doses should not be exceeded, especially in people with kidney disease. Diarrhoea is a common side effect at higher doses. Springer Nature+1

7. Curcumin (from turmeric)
   Curcumin has anti-inflammatory and antioxidant properties and has been studied in many conditions. In neuropathy models, it may reduce inflammatory signalling and oxidative stress, which could theoretically protect nerves. Absorption is low, so many products combine it with piperine or use special formulations. Side effects can include stomach upset and possible interaction with blood thinners. ScienceDirect+1

8. Resveratrol
   Resveratrol is a plant polyphenol with antioxidant and mitochondrial effects in laboratory studies. It may activate pathways that support cell survival and energy handling. Human data for CMT are lacking, so if used, it should be at standard supplement doses and monitored for interactions, especially with anticoagulants. ScienceDirect+1

9. Acetyl-L-carnitine
   Acetyl-L-carnitine supports mitochondrial fatty-acid transport and has been studied in some neuropathies. It may slightly improve nerve conduction and pain in certain conditions by supporting energy metabolism. Doses used in research are usually divided during the day. Side effects may include nausea and restlessness, and evidence in CMT is limited. ScienceDirect+1

10. N-acetylcysteine (NAC)
    NAC is a precursor of glutathione, a key antioxidant. It can reduce oxidative stress and inflammation in laboratory models, and has approved uses in other fields. In CMT, its role is experimental. It should be used only with medical guidance, because higher doses can cause gastrointestinal upset and interact with some drugs. ScienceDirect+1

---

Immunity-booster, regenerative and stem-cell-related drug concepts

These options are research-stage, not routine care. They show how science is trying to repair or protect nerves in CMT1A.

1. Neurotrophin-3 gene therapy (AAV1.NT-3)
   Neurotrophin-3 (NT-3) is a natural growth factor that supports Schwann cells and helps myelin repair and axon regeneration. Gene therapy using adeno-associated virus vectors to deliver NT-3 has improved nerve function in animal CMT1 models and early human work. The idea is to provide a long-term source of NT-3 from muscle, which then circulates to nerves. Current trials are small and carefully controlled, and dosing regimens are still being studied. Grantome+3PMC+3Institut de Myologie+3

2. PMP22-targeted combination therapy (PXT3003)
   PXT3003 combines low doses of baclofen, naltrexone, and sorbitol to lower PMP22 overexpression. In CMT1A trials, it improved disability scores and nerve function measures in some patients. The combination aims to rebalance gene expression and support remyelination rather than just masking pain. Dosing schedules are defined in trials, and further confirmatory studies are ongoing before wider approval. PMC+2ScienceDirect+2

3. Other gene-dose correcting strategies
   New approaches include small interfering RNAs and gene-editing tools designed to reduce excess PMP22. In animal models, these methods have partially normalised myelin and improved nerve conduction. However, they carry risks such as off-target gene editing and immune reactions. At present they remain in pre-clinical or very early clinical stages with experimental dosing and strict monitoring. Springer Nature+2ScienceDirect+2

4. Schwann cell or stem-cell–based therapies
   Researchers are exploring transplantation of Schwann cells or stem-cell–derived supportive cells into damaged nerves. The aim is to provide new myelin-producing cells and growth factors to help regenerate nerve fibres. These strategies are still experimental and involve complex procedures, immune-suppression questions, and long-term safety concerns, so no standard dosing or protocols exist for routine care. ScienceDirect+1

5. General immune and infection prevention (vaccination)
   While vaccines do not treat CMT1A directly, they support overall immunity and reduce risk of serious infections, which can worsen weakness or trigger hospital stays. Following national vaccination schedules for influenza, pneumonia, and other preventable infections helps maintain health and may avoid periods of prolonged immobilisation that harm muscles and nerves. Muscular Dystrophy Association+1

6. Future neuroprotective and anti-oxidant drugs
   Trials are exploring drugs that reduce oxidative stress, stabilise mitochondria, or modulate inflammatory pathways in hereditary neuropathies. For example, some agents target metabolic pathways or receptor systems involved in nerve injury. These drugs are at research stages, with carefully defined trial doses and safety checks, and are not yet available as standard treatment. ScienceDirect+2ScienceDirect+2

---

Surgical treatments

1. Foot deformity corrective surgery (e.g., cavus foot correction)
   Many people with CMT1A develop high arches, claw toes, and heel malalignment. When braces and therapy are not enough, orthopaedic surgeons can realign bones, release tight tendons, and sometimes transfer tendons to balance muscle forces. The goal is a more plantigrade (flat) foot that fits a brace better, reduces pain, and lowers risk of skin breakdown. OrthoInfo+1

2. Tendon transfer procedures
   In tendon transfer surgery, a working muscle’s tendon is moved to replace the function of a weak or paralyzed one, such as lifting the front of the foot (dorsiflexion). This can improve walking, reduce tripping, and may delay the need for more extensive bone surgery. It is usually combined with post-operative physiotherapy and bracing. OrthoInfo+1

3. Joint fusion (arthrodesis)
   If deformities are severe and joints are unstable or painful, fusion surgery permanently joins bones in a more functional position. For example, ankle or hindfoot fusion may provide stability for standing and walking. The trade-off is loss of motion at the fused joint, but better alignment and less pain can improve overall mobility. OrthoInfo+1

4. Hand surgery for deformities
   Severe clawing or contractures in the hands can interfere with grip and hygiene. Selected patients may benefit from tendon releases, transfers, or joint procedures to straighten fingers and improve function. These operations are carefully tailored to individual needs and followed by hand therapy and splinting. Muscular Dystrophy Association+1

5. Spine surgery (rare, for severe scoliosis)
   A minority of people with CMT develop significant spinal curvature that affects posture, breathing, or comfort. In these cases, spinal fusion or other corrective spinal surgery may be considered. This is major surgery with important risks and is only considered when bracing and physiotherapy are not enough. Muscular Dystrophy Association+1

---

Prevention and risk-reduction strategies

1. Avoid nerve-toxic medicines and toxins – Use lists from CMT organisations and always tell doctors you have CMT before starting new medicines. nhs.uk+1

2. Do regular physiotherapy and stretching – This prevents contractures, maintains strength, and delays deformities. CMT Australia+1

3. Use braces and orthoses early when recommended – Early bracing can prevent falls and protect joints from abnormal forces. www.slideshare.net+1

4. Protect feet and skin – Check feet daily, wear well-fitting shoes, and treat blisters or sores early to avoid ulcers and infections. OrthoInfo+1

5. Prevent falls at home – Remove tripping hazards, use handrails and grab bars, and ensure good lighting in halls and bathrooms. nhs.uk+1

6. Keep a healthy weight – Reduces load on weak ankles and knees and improves stamina. Muscular Dystrophy Association+1

7. Avoid smoking and heavy alcohol use – Both can further damage nerves and slow recovery from injury and surgery. Muscular Dystrophy Association+1

8. Control other health problems – Good management of diabetes, thyroid disease, and vitamin deficiencies helps protect nerves. ScienceDirect+1

9. Stay up-to-date with vaccinations – Preventable infections that cause long illness or bed rest can worsen weakness and mobility. Muscular Dystrophy Association+1

10. Attend regular specialist follow-up – Early identification of new problems allows prompt adjustments in therapy, bracing, or pain management. Muscular Dystrophy Association+1

---

When to see a doctor

You should see a neurologist or CMT specialist regularly even if symptoms feel stable, because the disease changes slowly and early interventions work best. Urgent review is important if you notice rapid worsening of weakness, new severe pain, sudden balance loss, or new bladder or bowel problems, as these are not typical of slow CMT progression and may signal another condition. New foot sores, infections, or sudden deformity need quick attention from doctors and orthopaedic specialists to prevent long-term damage. If pain medicines cause strong side effects such as extreme sleepiness, breathing trouble, mood changes, or signs of allergic reaction, they must be reviewed immediately. Genetic counselling visits are also helpful when planning a family or if other relatives develop similar symptoms. Muscular Dystrophy Association+2Monarch Initiative+2

---

What to eat and what to avoid

1. Eat a balanced, whole-food diet – Emphasise vegetables, fruits, whole grains, lean protein, and healthy fats to support general health and weight control. Muscular Dystrophy Association+1

2. Choose lean proteins – Fish, poultry, beans, and lentils support muscle repair without too much saturated fat. Oily fish also provide omega-3 fats that may help inflammation. ScienceDirect

3. Include calcium and vitamin-D-rich foods – Dairy products, fortified plant milks, and safe sunlight help bone strength, which is important when balance is reduced. Muscular Dystrophy Association+1

4. Stay well hydrated – Adequate fluid intake supports circulation and may reduce cramps and constipation from some medicines.

5. Limit added sugars and refined carbs – Reduces risk of weight gain and diabetes, which can further damage nerves. ScienceDirect+1

6. Avoid excess alcohol – Alcohol can directly harm peripheral nerves and worsen balance, increasing fall risk. ScienceDirect+1

7. Avoid crash diets and very low-calorie plans – Sudden weight loss can weaken muscles further and may cause nutrient deficiencies. Slow, supervised weight plans are safer.

8. Be cautious with unproven “nerve cure” supplements – Many products are marketed for nerve health but lack evidence and may interact with medicines. Always ask your doctor before starting them. ScienceDirect+1

9. Limit high-salt processed foods – Helps prevent high blood pressure, especially if taking certain pain medicines that affect kidneys.

10. Consider seeing a dietitian – A professional can design a plan that meets energy needs, respects cultural food preferences, and supports safe weight and bone health. Muscular Dystrophy Association+1

---

Frequently asked questions (FAQs)

1. Is there a cure for autosomal dominant Charcot-Marie-Tooth disease with focally folded myelin sheaths type 1A?
   At present there is no cure. All available treatments are supportive: they aim to manage symptoms, slow complications like deformities and falls, and maintain independence. Research into gene therapy and targeted drugs such as NT-3 gene therapy and PXT3003 is active but still experimental. ScienceDirect+2Springer Nature+2

2. Will everyone with CMT1A end up in a wheelchair?
   Most people with CMT1A remain able to walk, especially with braces, physiotherapy, and sometimes surgery. Some may need a wheelchair or scooter for long distances or later in life. Early rehabilitation and orthotic support can delay or reduce the need for full-time wheelchair use. Monarch Initiative+2Muscular Dystrophy Association+2

3. Why do I have “focally folded” myelin sheaths?
   In this subtype, the excess PMP22 protein disrupts normal myelin formation. Under a microscope, the myelin sometimes appears folded or thickened in specific spots along the nerve. This structural abnormality slows or blocks nerve signals, causing weakness and sensory loss, but it is not something you caused by lifestyle. Disease Ontology+2PMC+2

4. Can exercise make my CMT worse?
   Appropriate, supervised exercise usually helps, not harms. Over-tiring muscles to pain or exhaustion is not recommended, but regular moderate activity plus specific strengthening and stretching can improve function and delay complications. A physiotherapist who understands CMT can design a safe plan. CMT Australia+2Journal of Health and Allied Sciences NU+2

5. What is the difference between nerve pain and joint/muscle pain in CMT?
   Nerve (neuropathic) pain often feels burning, electric, or like pins-and-needles and may be worse at night. Musculoskeletal pain feels more like aching, stiffness, or sharp pain with movement. Different treatments work better for each type, so doctors ask detailed questions to choose the right combination of medicines and physical approaches. Charcot-Marie-Tooth Association+2CMT Australia+2

6. Are neuropathic pain drugs like gabapentin or duloxetine safe to take long term?
   These drugs have been used long term in many people with neuropathic pain. They can be effective but also carry risks such as sedation, weight gain, mood changes, or rare serious effects. Doctors aim for the lowest effective dose, monitor side effects, and regularly reassess whether the medicine is still needed. They should never be stopped suddenly without medical advice. Springer Nature+3FDA Access Data+3FDA Access Data+3

7. Should I start supplements on my own for my nerves?
   It is better not to start multiple supplements without medical guidance. Some, like B vitamins or vitamin D, are important when levels are low, but others may interact with medicines or be useless or harmful at high doses. A doctor can check blood tests and help you choose safe, evidence-based options. ScienceDirect+1

8. Can children with CMT1A play sports?
   Many children can take part in low-impact sports such as swimming, cycling, or adapted games, especially when advised by a physiotherapist. High-impact contact sports or activities with a high risk of ankle injuries may be less suitable. The focus is on enjoyment, safety, and avoiding fatigue or repeated injuries. Muscular Dystrophy Association+2CMT Australia+2

9. Will my CMT1A get worse quickly?
   CMT1A usually progresses slowly over many years. Symptoms often start in childhood or adolescence and gradually worsen. The rate is different for each person. Regular follow-up, exercise, and orthoses help manage changes and keep function as good as possible for as long as possible. CAGS+2Disease Ontology+2

10. Is pregnancy safe for someone with CMT1A?
    Many people with CMT1A have healthy pregnancies. However, weakness and balance changes can increase fall risk, and pain or fatigue may worsen. A high-risk obstetrician and neurologist should work together to plan care, review medicines, and support safe delivery. There is also a 50% chance of passing on the gene change, which can be discussed in genetic counselling. Disease Ontology+1

11. Can diet cure or reverse CMT1A?
    No diet can cure CMT1A or fix the underlying gene duplication. However, healthy eating supports weight control, bone strength, heart health, and energy levels, which are very important when muscles and nerves are already under stress. Diet is a supportive tool, not a cure. Muscular Dystrophy Association+1

12. How do I find a specialist or centre for CMT?
    International CMT foundations and neuromuscular organisations list specialist centres and clinics on their websites. Your local neurologist can also refer you to a neuromuscular clinic or genetic service. Being seen in a centre that regularly treats CMT can give access to expert physiotherapy, orthotics, and clinical trials. Monarch Initiative+2Muscular Dystrophy Association+2

13. Are gene tests useful if my diagnosis is already clear from symptoms?
    Genetic testing can confirm the exact subtype, such as PMP22 duplication for CMT1A, and may be needed for family planning, research trials, or future targeted treatments. However, it may not change current supportive treatment. A genetic counsellor can explain benefits and limitations for your situation. Disease Ontology+2Clinical Actionability+2

14. Can I join a clinical trial for CMT1A?
    Clinical trials test new drugs, gene therapies, or rehabilitation methods. Eligibility depends on age, disease stage, and other health factors. CMT registries, specialist centres, and trial databases list ongoing studies. Joining a trial is voluntary and requires informed consent after understanding potential risks and benefits. AFM Téléthon+3ClinicalTrials+3PMC+3

15. What is the most important thing I can do today to help myself?
    The most powerful steps are often simple: stay physically active within your limits, use braces or aids that improve safety, protect your feet and skin, keep a healthy weight, avoid nerve-toxic substances, and maintain regular check-ups with your CMT team. These actions, combined with emotional and social support, can greatly improve quality of life while research continues to look for disease-modifying treatments. Muscular Dystrophy Association+2Monarch Initiative+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 24, 2025.